WO2000052013A2 - Thiazoloindolinone compounds - Google Patents

Thiazoloindolinone compounds Download PDF

Info

Publication number
WO2000052013A2
WO2000052013A2 PCT/US2000/005192 US0005192W WO0052013A2 WO 2000052013 A2 WO2000052013 A2 WO 2000052013A2 US 0005192 W US0005192 W US 0005192W WO 0052013 A2 WO0052013 A2 WO 0052013A2
Authority
WO
WIPO (PCT)
Prior art keywords
compound
thiazolindolinone
methyl
indol
thiazolo
Prior art date
Application number
PCT/US2000/005192
Other languages
English (en)
French (fr)
Other versions
WO2000052013A3 (en
Inventor
Ambrish Vyas
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to MXPA01008910A priority Critical patent/MXPA01008910A/es
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Priority to BR0008677-0A priority patent/BR0008677A/pt
Priority to IL14480800A priority patent/IL144808A0/xx
Priority to KR1020017011094A priority patent/KR20020005606A/ko
Priority to JP2000602239A priority patent/JP2003532620A/ja
Priority to AU36110/00A priority patent/AU3611000A/en
Priority to US09/914,420 priority patent/US6492398B1/en
Priority to CA002361580A priority patent/CA2361580A1/en
Priority to EP00914762A priority patent/EP1159280A2/en
Publication of WO2000052013A2 publication Critical patent/WO2000052013A2/en
Publication of WO2000052013A3 publication Critical patent/WO2000052013A3/en
Priority to NO20014262A priority patent/NO20014262L/no
Priority to HK02103309.8A priority patent/HK1041692A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents

Definitions

  • the invention also relates in another aspect to methods for preparing various forms of such thiazolindolinone compound.
  • the present invention provides a thiazolindolinone compound having various forms that are useful as cyclin dependent kinase inhibitors.
  • Useful formulations may include the active ingredient and excipients, diluents, or carriers, formed into tablets, capsules, sprays, mouthwashes, lozenges, troches, pastilles, lollipops, suspensions, powders and the like, for application to the mucosa of the oral cavity.
  • Acceptable daily dosages of the CDK2 inhibitor for preventing/reducing the severity of epithtelial cytotoxicity side effects induced by chemotherapy and/or radiation therapy may be from about 0.1 to about 1000 mg/day, and preferably from about 50 to about 200 mg/day.

Landscapes

  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Cosmetics (AREA)
PCT/US2000/005192 1999-03-04 2000-03-01 Thiazoloindolinone compounds WO2000052013A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
AU36110/00A AU3611000A (en) 1999-03-04 2000-03-01 Thiazoloindolinone compounds
BR0008677-0A BR0008677A (pt) 1999-03-04 2000-03-01 Composto de tiazolindolinona, composição farmacêutica, e, métodos papa preparar um composto de tiazolindolinona, e de prevenção/reduçao da severidade dos efeitos colaterais de citotoxicidade epitelial da quimioterapia e/ou terapia de radiação
IL14480800A IL144808A0 (en) 1999-03-04 2000-03-01 Thiazoloindolinone compounds
KR1020017011094A KR20020005606A (ko) 1999-03-04 2000-03-01 티아졸로인돌리논 화합물
JP2000602239A JP2003532620A (ja) 1999-03-04 2000-03-01 チアゾロインドリノン化合物
MXPA01008910A MXPA01008910A (es) 1999-03-04 2000-03-01 Compuestos de tiazoloindolinona.
US09/914,420 US6492398B1 (en) 1999-03-04 2000-03-01 Thiazoloindolinone compounds
CA002361580A CA2361580A1 (en) 1999-03-04 2000-03-01 Thiazoloindolinone compounds
EP00914762A EP1159280A2 (en) 1999-03-04 2000-03-01 Thiazoloindolinone compounds
NO20014262A NO20014262L (no) 1999-03-04 2001-09-03 Tiazoloindolinon-forbindelser
HK02103309.8A HK1041692A1 (zh) 1999-03-04 2002-05-02 噻唑並吲滿酮化合物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9904930.6 1999-03-04
GBGB9904930.6A GB9904930D0 (en) 1999-03-04 1999-03-04 Thiazoloindolinone compounds

Publications (2)

Publication Number Publication Date
WO2000052013A2 true WO2000052013A2 (en) 2000-09-08
WO2000052013A3 WO2000052013A3 (en) 2000-12-28

Family

ID=10848912

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/005192 WO2000052013A2 (en) 1999-03-04 2000-03-01 Thiazoloindolinone compounds

Country Status (18)

Country Link
EP (1) EP1159280A2 (xx)
JP (1) JP2003532620A (xx)
KR (1) KR20020005606A (xx)
CN (1) CN1355807A (xx)
AU (1) AU3611000A (xx)
BR (1) BR0008677A (xx)
CA (1) CA2361580A1 (xx)
CZ (1) CZ20013187A3 (xx)
GB (1) GB9904930D0 (xx)
HK (1) HK1041692A1 (xx)
HU (1) HUP0200376A3 (xx)
IL (1) IL144808A0 (xx)
MX (1) MXPA01008910A (xx)
NO (1) NO20014262L (xx)
PL (1) PL351476A1 (xx)
TR (1) TR200102557T2 (xx)
WO (1) WO2000052013A2 (xx)
ZA (1) ZA200106826B (xx)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6369086B1 (en) * 1997-09-05 2002-04-09 Smithkline Beecham Corporation Substituted oxidole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors
WO2011125763A1 (ja) 2010-03-31 2011-10-13 小野薬品工業株式会社 手足症候群の予防および／または治療剤
US10583111B2 (en) 2017-12-13 2020-03-10 Onquality Pharmaceuticals China Ltd. Method for preventing or treating diseases associated with the inhibition of EGFR
US10987336B2 (en) 2018-04-16 2021-04-27 Onquality Pharmaceuticals China Ltd. Method of preventing or treating side effect of tumor therapy

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006060616A1 (en) * 2004-12-01 2006-06-08 Teva Gyógyszergyár Zàrtköruen Muködo Rèszvènytàrsasàg Processes for producing crystalline macrolides
UA103319C2 (xx) * 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Сполуки бензенсульфонамідтіазолу та -оксазолу$соединения бензенсульфонамидтиазола и -оксазола
JP4761000B1 (ja) * 2010-11-08 2011-08-31 小野薬品工業株式会社 手足症候群の予防および／または治療剤

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998050356A1 (en) * 1997-05-07 1998-11-12 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
WO1999015500A1 (en) * 1997-09-05 1999-04-01 Glaxo Group Limited Substituted oxindole derivatives as protein tyrosine kinase and as protein serine/threonine kinase inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998050356A1 (en) * 1997-05-07 1998-11-12 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
WO1999015500A1 (en) * 1997-09-05 1999-04-01 Glaxo Group Limited Substituted oxindole derivatives as protein tyrosine kinase and as protein serine/threonine kinase inhibitors

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6369086B1 (en) * 1997-09-05 2002-04-09 Smithkline Beecham Corporation Substituted oxidole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors
WO2011125763A1 (ja) 2010-03-31 2011-10-13 小野薬品工業株式会社 手足症候群の予防および／または治療剤
US8729056B2 (en) 2010-03-31 2014-05-20 Ono Pharmaceutical Co., Ltd. Preventive and/or therapeutic agent of hand-foot syndrome
US10583111B2 (en) 2017-12-13 2020-03-10 Onquality Pharmaceuticals China Ltd. Method for preventing or treating diseases associated with the inhibition of EGFR
US10987336B2 (en) 2018-04-16 2021-04-27 Onquality Pharmaceuticals China Ltd. Method of preventing or treating side effect of tumor therapy

Also Published As

Publication number Publication date
CA2361580A1 (en) 2000-09-08
HUP0200376A2 (en) 2002-06-29
NO20014262D0 (no) 2001-09-03
CZ20013187A3 (cs) 2002-02-13
WO2000052013A3 (en) 2000-12-28
MXPA01008910A (es) 2002-03-27
BR0008677A (pt) 2002-01-08
HK1041692A1 (zh) 2002-07-19
HUP0200376A3 (en) 2003-07-28
PL351476A1 (en) 2003-04-22
CN1355807A (zh) 2002-06-26
AU3611000A (en) 2000-09-21
IL144808A0 (en) 2002-06-30
TR200102557T2 (tr) 2007-01-22
EP1159280A2 (en) 2001-12-05
NO20014262L (no) 2001-10-30
KR20020005606A (ko) 2002-01-17
ZA200106826B (en) 2003-02-25
GB9904930D0 (en) 1999-04-28
JP2003532620A (ja) 2003-11-05

Similar Documents

Publication Publication Date Title
ES2199156T3 (es) Derivados de aza-oxindol sustituidos.
US6369086B1 (en) Substituted oxidole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors
US7897607B2 (en) Cyclic compounds
EP1732920B1 (en) Thiophene derivatives as chk 1 inhibitors
ES2206729T3 (es) Compuestos heteroaromaticos biciclicos como inhibidores de la proteina tirosina quinasa.
AU781028B2 (en) Imidazo (1,3,5) triazinones and the use thereof
JP4285602B2 (ja) 抗炎症剤
US7189716B2 (en) Tyrosine kinase inhibitors
US6624171B1 (en) Substituted aza-oxindole derivatives
CZ139097A3 (cs) 6-Arylpyrido[2,3-d]pyrimidiny a naftyridiny a farmaceutické prostředky na jejich bázi
CZ302486B6 (cs) N-6-Substituovaný 7-deazapurin, zpusob jeho prípravy a farmaceutická kompozice s jeho obsahem
JP6797923B2 (ja) Ａｌｋおよびｓｒｐｋ阻害剤ならびに使用方法
CZ20023945A3 (cs) Substituované pyrrolopyridinové deriváty pro použití jako inhibitory fosfodiesterázy
KR20190104632A (ko) 트라이사이클릭 자이라제 억제제
PT1246623E (pt) Compostos específicos para o receptor de adenosina a1,a2a e a3 e as suas utilizações
EP1325009B1 (en) Amino-substituted tetracyclic compounds useful as anti-inflammatory agents and pharmaceutical compositions comprising same
WO2004016605A1 (en) 2-aminopyrimidine derivatives as adenosine a1 and a2a receptor antagonists
KR20010006509A (ko) 5,7-이치환된 4-아미노피리도[2,3-ｄ]피리미딘 화합물 및 아데노신 키나제 억제제로서의 이의 용도
WO2000052013A2 (en) Thiazoloindolinone compounds
US6492398B1 (en) Thiazoloindolinone compounds
JP2003519151A (ja) トリアゾロトリアジノンおよびそれらの使用
PL165413B1 (pl) Sposób wytwarzania nowych pochodnych 6-arylo-5,6-dwuhydroimidazo [2,1-b] tiazolu PL PL
JP2004521907A (ja) ２−アルコキシフェニル置換されたイミダゾトリアジノン
EP1798232A1 (en) Inhibitors of cysteine proteases, the pharmaceutical compositions thereof and their therapeutic applications
WO2021168341A1 (en) Solid forms of 1-(5-(3-(7-(3-fluorophenyl)-3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-n,n-dimethylmethanamine

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 00804616.6

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2001/805/KOL

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 144808

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 513447

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 36110/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2001/06826

Country of ref document: ZA

Ref document number: 200106826

Country of ref document: ZA

ENP Entry into the national phase

Ref document number: 2361580

Country of ref document: CA

Ref document number: 2361580

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 09914420

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2000914762

Country of ref document: EP

Ref document number: 1020017011094

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/008910

Country of ref document: MX

Ref document number: 2001/02557

Country of ref document: TR

ENP Entry into the national phase

Ref document number: 2000 602239

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PV2001-3187

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 2000914762

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1020017011094

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: PV2001-3187

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 2000914762

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: PV2001-3187

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 1020017011094

Country of ref document: KR